[
  {
    "criterion": "Provides a correct explanation of the off-label use of GLP-1 agonists in obesity.",
    "axis": "accuracy",
    "point": 5
  },
  {
    "criterion": "Fails to mention potential side effects of off-label use of GLP-1 agonists in obesity.",
    "axis": "completeness",
    "point": -3
  },
  {
    "criterion": "Asks for clarification about the user's query to better understand their needs.",
    "axis": "context_awareness",
    "point": 5
  },
  {
    "criterion": "Provides overly technical or jargon-heavy information that may be difficult for a non-expert to understand.",
    "axis": "communication_quality",
    "point": -2
  },
  {
    "criterion": "Incorrectly states that GLP-1 agonists are approved for treating obesity.",
    "axis": "accuracy",
    "point": -9
  },
  {
    "criterion": "Provides a brief summary of the available research on off-label use of GLP-1 agonists in obesity, without overwhelming the user with too much information.",
    "axis": "completeness",
    "point": 4
  },
  {
    "criterion": "Mentions the importance of consulting a healthcare professional before using GLP-1 agonists off-label for obesity treatment.",
    "axis": "completeness",
    "point": 5
  },
  {
    "criterion": "Fails to provide any information about the off-label use of GLP-1 agonists in obesity.",
    "axis": "completeness",
    "point": -10
  },
  {
    "criterion": "Provides a clear and concise explanation of the off-label use of GLP-1 agonists in obesity, without using overly technical language.",
    "axis": "communication_quality",
    "point": 6
  }
]